Sansure Biotech's (SHA:688289) subsidiary, Zhongshan Sansure Haiji Biopharmaceutical, completed the domestic drug filing for the recombinant human growth hormone injection's workshop at China's National Medical Products Administration, according to a Shanghai Stock Exchange filing on Tuesday.
The Chinese molecular diagnostics and genetic testing products manufacturer will build a new production line in Zhongshan Torch High-Tech Industrial Development Zone, China, for the product after the approval.
The company's shares slipped more than 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.